Your browser doesn't support javascript.
loading
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group.
Janez, Andrej; Muzurovic, Emir; Bogdanski, Pawel; Czupryniak, Leszek; Fabryova, Lubomira; Fras, Zlatko; Guja, Cristian; Haluzik, Martin; Kempler, Peter; Lalic, Nebojsa; Mullerova, Dana; Stoian, Anca Pantea; Papanas, Nikolaos; Rahelic, Dario; Silva-Nunes, José; Tankova, Tsvetalina; Yumuk, Volkan; Rizzo, Manfredi.
Afiliación
  • Janez A; Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia. andrej.janez@kclj.si.
  • Muzurovic E; Department of Internal Medicine, Endocrinology Section, Clinical Centre of Montenegro, Faculty of Medicine, University of Montenegro, Podgorica, Montenegro.
  • Bogdanski P; Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, University of Medical Sciences, Poznan, Poland.
  • Czupryniak L; Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warszawa, Poland.
  • Fabryova L; MetabolKLINIK sro, Department for Diabetes and Metabolic Disorders, Lipid Clinic, MED PED Centre, Biomedical Research Centre of Slovak Academy of Sciences, Slovak Health University, Bratislava, Slovak Republic.
  • Fras Z; Preventive Cardiology Unit, Division of Medicine, University Medical Centre Ljubljana and Chair of Internal Medicine, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Guja C; Clinic of Diabetes, Nutrition and Metabolic Diseases, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
  • Haluzik M; Diabetes Centre, Institute for Clinical and Experimental Medicine, Vídenská 1958/9, 140 21, Prague 4, Czech Republic.
  • Kempler P; Department of Medicine and Oncology, Semmelweis University, Budapest, Hungary.
  • Lalic N; Faculty of Medicine, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia.
  • Mullerova D; Faculty of Medicine in Pilsen, Department of Public Health and Preventive Medicine and Faculty Hospital in Pilsen, 1st Internal Clinic, Charles University, Pilsen, Czech Republic.
  • Stoian AP; Diabetes, Nutrition and Metabolic Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Papanas N; Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
  • Rahelic D; Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.
  • Silva-Nunes J; Catholic University of Croatia School of Medicine, Zagreb, Croatia.
  • Tankova T; Josip Juraj Strossmayer, University of Osijek School of Medicine, Osijek, Croatia.
  • Yumuk V; NOVA Medical School, New University of Lisbon, Lisbon, Portugal.
  • Rizzo M; Department of Endocrinology, Diabetes and Metabolism, Unidade Local de Saúde São José, Lisbon, Portugal.
Diabetes Ther ; 15(9): 1865-1892, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38990471
ABSTRACT
The increasing global incidence of obesity and type 2 diabetes mellitus (T2D) underscores the urgency of addressing these interconnected health challenges. Obesity enhances genetic and environmental influences on T2D, being not only a primary risk factor but also exacerbating its severity. The complex mechanisms linking obesity and T2D involve adiposity-driven changes in ß-cell function, adipose tissue functioning, and multi-organ insulin resistance (IR). Early detection and tailored treatment of T2D and obesity are crucial to mitigate future complications. Moreover, personalized and early intensified therapy considering the presence of comorbidities can delay disease progression and diminish the risk of cardiorenal complications. Employing combination therapies and embracing a disease-modifying strategy are paramount. Clinical trials provide evidence confirming the efficacy and safety of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). Their use is associated with substantial and durable body weight reduction, exceeding 15%, and improved glucose control which further translate into T2D prevention, possible disease remission, and improvement of cardiometabolic risk factors and associated complications. Therefore, on the basis of clinical experience and current evidence, the Eastern and Southern Europe Diabetes and Obesity Expert Group recommends a personalized, polymodal approach (comprising GLP-1 RAs) tailored to individual patient's disease phenotype to optimize diabetes and obesity therapy. We also expect that the increasing availability of dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists will significantly contribute to the modern management of the cardiometabolic continuum.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Diabetes Ther Año: 2024 Tipo del documento: Article País de afiliación: Eslovenia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Diabetes Ther Año: 2024 Tipo del documento: Article País de afiliación: Eslovenia Pais de publicación: Estados Unidos